Búsqueda | BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas

1.

Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06.

Lee, J S; Scott, C; Komaki, R; Fossella, F V; Dundas, G S; McDonald, S; Byhardt, R W; Curran, W J.

J Clin Oncol ; 14(4): 1055-64, 1996 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-8648357

2.

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.

Fossella, F V; Lee, J S; Murphy, W K; Lippman, S M; Calayag, M; Pang, A; Chasen, M; Shin, D M; Glisson, B; Benner, S.

J Clin Oncol ; 12(6): 1238-44, 1994 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-7911160

3.

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.

Fossella, F V; Lee, J S; Shin, D M; Calayag, M; Huber, M; Perez-Soler, R; Murphy, W K; Lippman, S; Benner, S; Glisson, B.

J Clin Oncol ; 13(3): 645-51, 1995 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-7884425

4.

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

Fossella, F V; DeVore, R; Kerr, R N; Crawford, J; Natale, R R; Dunphy, F; Kalman, L; Miller, V; Lee, J S; Moore, M; Gandara, D; Karp, D; Vokes, E; Kris, M; Kim, Y; Gamza, F; Hammershaimb, L.

J Clin Oncol ; 18(12): 2354-62, 2000 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-10856094

5.

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

Bruno, R; Hille, D; Riva, A; Vivier, N; ten Bokkel Huinnink, W W; van Oosterom, A T; Kaye, S B; Verweij, J; Fossella, F V; Valero, V; Rigas, J R; Seidman, A D; Chevallier, B; Fumoleau, P; Burris, H A; Ravdin, P M; Sheiner, L B.

J Clin Oncol ; 16(1): 187-96, 1998 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-9440742

6.

Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.

Semin Radiat Oncol ; 12(1 Suppl 1): 46-9, 2002 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-11917284

7.

Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.

Fossella, F V.

Semin Oncol ; 26(3 Suppl 11): 4-8, 1999 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-10458203

8.

Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.

Fossella, F V.

Semin Oncol ; 26(5 Suppl 16): 17-23; discussion 41-2, 1999 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-10585004

9.

Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.

Fossella, F V; Lee, J S; Berille, J; Hong, W K.

Semin Oncol ; 22(2 Suppl 4): 22-9, 1995 Apr.

Artículo en Inglés | MEDLINE | ID: mdl-7740327

10.

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.

Shepherd, F A; Fossella, F V; Lynch, T; Armand, J P; Rigas, J R; Kris, M G.

Semin Oncol ; 28(1 Suppl 2): 4-9, 2001 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-11284623

11.

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.

Weiss, G J; Rosell, R; Fossella, F; Perry, M; Stahel, R; Barata, F; Nguyen, B; Paul, S; McAndrews, P; Hanna, N; Kelly, K; Bunn, P A.

Ann Oncol ; 18(3): 453-60, 2007 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-17322539

12.

Second-line chemotherapy for non-small-cell lung cancer.

Fossella, F V.

Curr Oncol Rep ; 2(1): 96-101, 2000 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-11122830

13.

New options in the treatment of non-small cell lung cancer.

Fossella, F; Rigas, J R; Belani, C P.

Anticancer Drugs ; 10 Suppl 1: S25-8, 1999 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-10630365

14.

Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.

Glisson, B; Lee, J S; Palmer, J; Fossella, F; Shin, D M; Murphy, W K; Perez-Soler, R; Hong, W K.

Cancer ; 82(2): 301-8, 1998 Jan 15.

Artículo en Inglés | MEDLINE | ID: mdl-9445186

15.

Phase I study of paclitaxel administered by ten-day continuous infusion.

Shade, R J; Pisters, K M; Huber, M H; Fossella, F; Perez-Soler, R; Shin, D M; Kurie, J; Glisson, B; Lippman, S; Lee, J S.

Invest New Drugs ; 16(3): 237-43, 1998.

Artículo en Inglés | MEDLINE | ID: mdl-10360603

BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas - MTCI

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06.

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.

Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.

Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.

Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer.

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.

Second-line chemotherapy for non-small-cell lung cancer.

New options in the treatment of non-small cell lung cancer.

Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.

Phase I study of paclitaxel administered by ten-day continuous infusion.